We developeda protocolto studyinterferenceby cefotaxime and one of its major metaboliteswith 24 common chemical tests. Serum poolssimulatingspecimensfromhealthyadults of both sexes, pregnant women, patients with liver disease, cardiac disease, or renal disease, and patients receiving gentamicin and tobramycin were supplemented with high and low concentrationsof cefotaximeand desacetylcefotaxime. Using a discrete analyzer (the American Monitor Parallel), we tested 12 replicatesamples from each conditionfor 24 analytes. Although statistically significant changes were found in many tests, 85% of the differences were less than 15% of the controlvalue and more than half were less than 5%. this pool was from patients whose sera showed abovenormal activity for aspartate aminotransferaae and alkaline phosphatase. Myocardial infarction pool: this was the excess from specimens sent to the laboratory with a request for assay of "cardiac" enzymes; they showed above-normal content of creatine kinase MB isoenzyme, alpha-hydroxybutyrate dehydrogenase, or a "flipped" lactate dehydrogenase isoenzyme 1/2 ratio. The renal disease pool contained any specimen with an above-normal concentration of serum urea nitrogen or creatinine. The pools for gentamicin and tobramycin were from specimens sent for determination of concentrations of the respective drug, for which the concentration was in the therapeutic range.
15% of the controlvalue and more than half were less than 5%. The apparent concentrationof creatininewas notsignificantlychanged. Test resultsfor phosphoruswere increased in patients who were receiving gentamicin and tobramycin.
No other changes were consideredclinicallysignificant. with common laboratory tests have been proposed. We report here the development and application of such a protocol.
A drug may interfere with laboratory tests in several ways, one of which is by direct interference with the chemistry of the determination, causing an increase or a decrease in the measured colored product, or inhibiting an enzyme reaction that is part of the test procedure.
The drug may displace or enter into a binding reaction that perturbs the final measurement or it may result in fluorescence, color, or turbidity and thereby interfere with the measurement. A metabolite of the drug also may interfere by one of the mechanisms cited above. Or the drug may introduce metabolic changes in vivo that induce chemical changes in the individual receiving the drug. This study protocol was designed for use in investigating direct chemical interference with commonly performed clinical chemistry tests.
Previous studies of drug interferences generally have dealt only with samples from normal individuals, failing to take into account possible changes in pathological specimens. We therefore include in this study various types of specimens commonly encountered in routine clinical laboratory practice. this pool was from patients whose sera showed abovenormal activity for aspartate aminotransferaae and alkaline phosphatase. Myocardial infarction pool: this was the excess from specimens sent to the laboratory with a request for assay of "cardiac" enzymes; they showed above-normal content of creatine kinase MB isoenzyme, alpha-hydroxybutyrate dehydrogenase, or a "flipped" lactate dehydrogenase isoenzyme 1/2 ratio. The renal disease pool contained any specimen with an above-normal concentration of serum urea nitrogen or creatinine. The pools for gentamicin and tobramycin were from specimens sent for determination of concentrations of the respective drug, for which the concentration was in the therapeutic range.
Test pooi preparation.

Pools were collected
by adding appropriate serum specimens to previously frozen specimen pools. When collection was complete, the pool was thawed, well mixed, filtered, and apportioned into subpools to contain the drug and its metabolite to be studied. We prepared a solution of the test drug or its metabolite in sodium phosphate buffer (67 mmol/L, pH 7.0). The high drug concntrations were prepared by adding 210 pL of a 4 g/L solution of pure cefotaxime, dissolved in buffer, to 21 mL of serum. To prepare the low-drug aliquota, we added 1 mL of the previously prepared high-concentration pool to 19 mL of serum pool. The control sera were prepared by adding 200 MJ.of the sodium phosphate buffer to 20 mL of serum.
The metabolite pool aliquots
were prepared similarly except that 220 L of metabolite solution containing 2 g of pure desacetylcefotaxime
per liter, in buffer, was added to 22 mL of serum to make the high-concentration aliquots, and 2 mL of this aliquot was diluted with 18 mL of serum to make the low-concentration aliquots.
We therefore set up a total of 40 (five drug conditions multiplied by eight populations) different test conditions, and performed each test in 12 replicates. Furthermore, we designed the protocol to test each pool condition within a single instrument run. For example, all 60 subpool samples (five drug conditions multiplied by 12 replicates) from the pooled sera from healthy men were run in one assay, to eliminate day-to-day variation in the chemical analysis.
Drug studied. Cefotaxime is a potent, widely used, thirdgeneration cephalosporin with a broad spectrum of activity (5, 6). In human serum the major detectable metabolite is deaacetylcefotaxime (7, 8) . (Pure cefotaxime and desacetylcefotaxime were supplied through the courtesy of HoechstRoussel Pharmaceuticals, Inc., Somerville, NJ 08876.) Two other metabolites, designated UP1 and UP2, may also be found in patients with compromised kidney function. When renal function is normal, the concentration of desacetylcefo- We studied the effects of cefotaxime at 2 and 40 mgfL, values chosen to simulate trough and peak serum concentrations expected during the usual intermittent intravenous dosing. The concentrations of desacetylcefotaxime studied, 2 and 20 mg/L, were selected to approximate the greatest "typical" concentrations in a patient with normal and abnormal renal function.
Instrument and test method.
A study of this magnitude requires a high-speed, high-performance automated chemical analyzer.
We Quality control. All tests for a specific population were completed in a single run. Conventional run-to-run qualitycontrol data are therefore not germane to this study.
Statistical methods.
The range, median, and mean of the test values were computed for each of the 24 tests and eight populations. We used a one-way ov F-test to test for statistically significant differences among the five drug conditions within each test-population combination. When differences were significant at the p = 0.001 level, we then compared drug-and met bolite-group results with the results for the no-drug control groups. We also used Student's t-test for separate varance estimates, considering differ-
distributed. These methods test whether the differences between mean values of the control samples and drug/metabolite samples are greater than can be explained by analytical variation.
Results
The drug effects displayed in Table 1 were defined as the difference between the average of the high-and low-drug groups and the no-drug control. Similarly, the metabolite effects were defined as the difference between the average of the high-and low-metabolite groups and the no drug control. Although not shown in Table 1 , we also individually compared the high-and low-drug groups and the high-and low-metabolite groups with the no-drug control. As seen from Table 1 , all tests except those for triglyceride, aspartate aminotransferase, alanine anunotransferase, and creatiine had statistically significant drug or metabolite effects. There were many more significant metabolite effects than drug effects. When both metabolite and drug effects were statistically significant, the signs and magnitudes of the effects were consistent except for unbound ironbinding concentration in the liver disease population, where the drug effect was positive and the metabolite effect negative. The magnitudes of the drug and metabolite effects ranged from 1 to 80% of the control means; over half of the effects were less than 5% of the control mean, and 85% of the effects were less than 15% of the control mean. Table 2 summarizes the statistically significant changes observed by adding cefotaxime or its metabolite desacetylce-. fotaxime to pools of serum from different populations.
The column labeled "number of changes" indicates the number of subpools that had a statistically significant variation from the control pool for that population. "Magnitude" indicates the range of percent changes from the control pool.
Discussion
In interpreting the results displayed in Table 1 , we must keep in mind the important distinction between statistical significance and medical significance in test data. The latter implies that a statistically significant effect would also lead to an incorrect medical decision in a clinical practice. It is important that investigators, in a study such as this, make a judgment concerning the medical significance of the observed changes. Without it, the reader may be left with the impression that medically significant changes have cccurred when in fact the changes are of minimal importance. Any judgment about medical significance must be subjective. Our judgment may be rather liberal. To be a medically significant change, we required that the variation be likely to cause a change in diagnosis or management.
The only other guidelines we know of against which to test these changes are Tonk's formula (10) and Barnett's analytic goals (11).
Tonk's formula was an empirical formula devised as a goal for satisfactory analytical performance.
It states that satisfactory quality-control performance should be less than #{188} the normal range for an analyte. It seems reasonable that the same rule might apply to judging the medical significance of drug-induced variation in analysis.
Barnett's analytical goals resulted from a questionnaire sent to 125 internists and 100 general practitioners. This questionnaire attempted to define the coefficient of variation that would signal a significant change in laboratory results. We have doubled the average of responses by the two physician groups to approximate the 95% confidence limits (Table 3) . Other test changes that might be medically significant have characteristics that strongly suggest that the variations were due to spurious laboratory results. With the metabolite, creatine kinase was significantly increased in serum of the normal male population.
There was much greater variability between replicate samples in this particular population and condition than in others. The apparent changes were most probably due to spurious laboratory test results.
Sodium and potassium values were moderately increased in the gentamicin population with both drug and metabo- As we performed this study according to the protocol that we had developed, we became aware of certain important factors. A study of this magnitude involves large numbers of specimens collected over a period of time and under varying conditions.
It is important that there be strict attention to detail in the collection, mixing, augmenting, and aliquoting of the specimens. An error in dilution of one of the specimens could easily cause a spurious result. With almost 12000 individual test results resulting from the study, the need for reliable, high-speed, automated chemical analyzers is essential. There must be simple methods for collection of the test results, and transfer of the results to the computer for data analysis. In our study it was necessary for us to manually collate test results on worksheets before entering data into the computer, because a data link between the chemical analyzer and computer had not yet been established. In calculating the cost of such a study, data prepara- 
Gamma-glutamyltransferase
The availability of high-speed, multichannel chemical analyzers capable of storing or transferring data for subsequent computer analysis now allows us to systematically perform drug interference studies. Such studies can be be undertaken in medical care institutions having access to large numbers of abnormal patients' specimens.
The high
cost of such studies mandates the involvement of pharmaceutical firms in providing the financial support to perform these studies.
